METHODS OF TREATING ALCOHOL ABUSE DISORDER

• US 20190314457A1
• Filed: 10/13/2017
• Published: 10/17/2019
• Est. Priority Date: 10/14/2016
• Status: Active Grant

• Current Assignee: Atonomics A/S, Trustees Of Columbia University In The City Of New York (Columbia University)
• Original Assignee: Trustees Of Columbia University In The City Of New York (Columbia University)
• Inventors: WALEWSKI, Jose Leonardo, BERK, Paul David
• Granted Patent: US 11,154,591 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61P 25/32 Alcohol-abuse

Abstract

The invention provides for methods of treating alcohol abuse disorder.

Claims

1. A method for treating alcohol abuse disorder in a subject, the method comprising administering to a subject an effective amount of Spexin.

12. The method of any one of claims 1-11, wherein the subject is a human or non-human animal.

13. The method of any one of claims 1-11, wherein the subject is male and consumes more than 3 ounces of alcohol per day.

14. The method of any one of claims 1-11, wherein the subject is female and consumes more than 1.5 ounces of alcohol per day.

15. The method of any one of claims 1-11, wherein the subject is over 60 years of age and consumes more than 1.5 ounces of alcohol per day.

16. The method of any one of claims 1-11, wherein the amount administered results in at least about 1 ng/ml in the serum.

17. The method of any one of claims 1-11, wherein the amount administered results in at least about 3 ng/ml in the serum.

18. The method of any one of claims 1-11, wherein the amount administered results in at least about 10 ng/ml in the serum.

19. The method of any one of claims 1-11, wherein the amount administered results in at least about 30 ng/ml in the serum.

20. The method of any one of claims 1-11, wherein the amount administered results in at least about 100 ng/ml in the serum.

21. The method of any one of claims 1-11, wherein the amount administered results in at least about 250 ng/ml in the serum.

22. The method of any one of claims 1-11, wherein the amount administered results in at least about 500 ng/ml in the serum.

23. The method of any one of claims 1-11, wherein the polypeptide is administered at least once daily or at least twice daily.

24. The method of any one of claims 1-11, wherein the polypeptide is administered for at least 1 week, for at least 2 weeks, for at least 3 weeks, for at least 4 weeks, for at least 5 weeks, for at least 6 weeks, for at least 8 weeks, for at least 10 weeks, for at least 12 weeks, for at least 24 weeks, or for at least 48 weeks.

25. The method of any one of claims 1-11, wherein the polypeptide is administered for at least 1 year, for at least 1.5 years, for at least 2 years, for at least 2.5 years, or for at least 5 years.

2. A method for treating alcohol abuse disorder in a subject, the method comprising administering to a subject in need thereof a polypeptide comprising SEQ ID NO:

1, or a pharmaceutically acceptable salt thereof.

3. A method for treating alcohol abuse disorder in a subject, the method comprising administering to a subject in need thereof a polypeptide comprising SEQ ID NO:

3 or 4, or a pharmaceutically acceptable salt thereof.

7. The method of claims 3-5, wherein the consumption of alcohol by the subject is reduced compared to the consumption of alcohol by the subject before administration of the polypeptide.

4. A method for reducing alcohol consumption in a subject afflicted with alcohol abuse disorder, the method comprising administering to the subject an effective amount of Spexin.

5. A method for reducing alcohol consumption in a subject afflicted with alcohol abuse disorder, the method comprising administering to the subject a polypeptide comprising SEQ ID NO:

1, or a pharmaceutically acceptable salt thereof.

6. A method for reducing alcohol consumption in a subject afflicted with alcohol abuse disorder, the method comprising administering to the subject a polypeptide comprising SEQ ID NO:

3 or 4, or a pharmaceutically acceptable salt thereof.

8. A method for promoting the cessation of alcohol consumption in a subject afflicted with alcohol abuse disorder, the method comprising administering to the subject an effective amount of Spexin.

9. A method for promoting the cessation of alcohol consumption in a subject afflicted with alcohol abuse disorder, the method comprising administering to the subject a polypeptide comprising SEQ ID NO:

1, or a pharmaceutically acceptable salt thereof.

10. A method for promoting the cessation of alcohol consumption in a subject afflicted with alcohol abuse disorder, the method comprising administering to the subject a polypeptide comprising SEQ ID NO:

3 or 4, or a pharmaceutically acceptable salt thereof.

11. The method of claims 8-10, wherein the subject ceases consumption of alcohol.